Cost-effectiveness of routine adolescent vaccination with an M72/AS01<sub>E</sub>-like tuberculosis vaccine in South Africa and India.
other
Where this comes from
- Record sourced from PubMed, PMID 35105879.
- Also identified by DOI 10.1038/s41467-022-28234-7 and PMC identifier 8807591.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
The M72/AS01<sub>E</sub> tuberculosis vaccine showed 50% (95%CI: 2-74%) efficacy in a phase 2B trial in preventing active pulmonary tuberculosis disease, but potential cost-effectiveness of adolescent immunisation is unknown. We estimated the impact and cost-effectiveness of six scenarios of routine adolescent M72/AS01<sub>E</sub>-like vaccination in South Africa and India. All scenarios suggested an M72/AS01<sub>E</sub>-like vaccine would be highly (94-100%) cost-effective in South Africa compared to a cost-effectiveness threshold of $2480/disability-adjusted life-year (DALY) averted. For India, a prevention of disease vaccine, effective irrespective of recipient's M. tuberculosis infection status at time of administration, was also highly likely (92-100%) cost-effective at a threshold of $264/DALY averted; however, a prevention of disease vaccine, effective only if the recipient was already infected, had 0-6% probability of cost-effectiveness. In both settings, vaccinating 50% of 18 year-olds was similarly cost-effective to vaccinating 80% of 15 year-olds, and more cost-effective than vaccinating 80% of 10 year-olds. Vaccine trials should include adolescents to ensure vaccines can be delivered to this efficient-to-target population.
Medical subject headings
- Cost-Benefit Analysis
- Tuberculosis Vaccines
- Vaccination